银屑病治疗药物——苏金单抗(Cosentyx)全球最新价格

全球首个白细胞介素17(IL-17)单克隆抗体Cosentyx(secukinumab)，分别于2015年1和2016年1月获欧盟和美国批准强直性脊柱炎(AS)适应症。此次批准，使Cosentyx成为继抗TNF单抗药物上市后16年来强直性脊柱炎(AS)临床治疗方面取得的首个新的治疗突破。强直性脊柱炎(AS)是一种常见的炎症性关节疾病，导致脊柱及身体其他部位发炎。如果不能得到有效治疗，长年累月的炎症将会导致不可逆的脊柱损伤，导致患者终身疼痛和残疾，并且对患者的日常生活带来严重的负面影响。发展为重度AS的患者，若不治疗，多达70%会在10至15年内发生可怕的脊柱-关节融合，致残率非常高。据估计，在英国大约有20万人受强直性脊柱炎(AS)困扰。

Cosentyx(secukinumab), the world's first interleukin 17(IL-17) monoclonal antibody, was approved for ankylosing spondylitis (AS) in the European Union and the US in January 2015 and January 2016 respectively. With this approval, Cosentyx is the first new treatment breakthrough for ankylosing spondylitis (AS) in the 16 years since the introduction of an anti-TNF monoclonal antibody. Ankylosing spondylitis (AS) is a common inflammatory joint disease that causes inflammation of the spine and other parts of the body. If not treated effectively, chronic inflammation can lead to irreversible spinal damage, lifelong pain and disability, and a severe negative impact on daily life. Without treatment, up to 70% of patients who develop severe AS will develop the dreaded spine-joint fusion within 10 to 15 years, with a very high disability rate. It is estimated that around 200,000 people in the UK are affected by ankylosing spondylitis (AS).

印度代购提示您，本品中国价格

原研药：暂无资料

仿制药：（150mg/管）2200元

中国医保价格：暂无资料

印度代购提示您，本品印度价格

原研药：暂无资料

仿制药：（150mg/瓶）18200卢比

印度代购提示您，本品美国价格

原研药：(150mg/管)8692.57美元/套

仿制药：暂无资料

印度代购提示您，本品日本价格

原研药：（150mg/管）74686日元/套

仿制药：暂无资料